Genfit 향후 성장

Future 기준 점검 5/6

Genfit (는) 각각 연간 77.1% 및 8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 110.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 51% 로 예상됩니다.

핵심 정보

77.1%

이익 성장률

110.72%

EPS 성장률

Biotechs 이익 성장	60.5%
매출 성장률	8.0%
향후 자기자본이익률	50.97%
애널리스트 커버리지	Good
마지막 업데이트	22 May 2026

최근 향후 성장 업데이트

Recent updates

분석 기사 • Sep 23

These Analysts Just Made An Downgrade To Their Genfit S.A. (EPA:GNFT) EPS Forecasts

The analysts covering Genfit S.A. ( EPA:GNFT ) delivered a dose of negativity to shareholders today, by making a...

분석 기사 • Jul 16

Some Analysts Just Cut Their Genfit S.A. (EPA:GNFT) Estimates

The latest analyst coverage could presage a bad day for Genfit S.A. ( EPA:GNFT ), with the analysts making...

분석 기사 • Jun 11

Shareholders Will Probably Not Have Any Issues With Genfit S.A.'s (EPA:GNFT) CEO Compensation

Key Insights Genfit's Annual General Meeting to take place on 17th of June Salary of €405.6k is part of CEO M...

분석 기사 • May 06

Improved Revenues Required Before Genfit S.A. (EPA:GNFT) Stock's 29% Jump Looks Justified

Genfit S.A. ( EPA:GNFT ) shares have had a really impressive month, gaining 29% after a shaky period beforehand. Taking...

분석 기사 • May 02

Solid Earnings Reflect Genfit's (EPA:GNFT) Strength As A Business

When companies post strong earnings, the stock generally performs well, just like Genfit S.A.'s ( EPA:GNFT ) stock has...

분석 기사 • Apr 29

These 4 Measures Indicate That Genfit (EPA:GNFT) Is Using Debt Reasonably Well

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

분석 기사 • Nov 16

Genfit S.A. (EPA:GNFT) Not Doing Enough For Some Investors As Its Shares Slump 25%

The Genfit S.A. ( EPA:GNFT ) share price has softened a substantial 25% over the previous 30 days, handing back much of...

분석 기사 • Sep 27

We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit

After announcing healthy earnings, Genfit S.A.'s ( EPA:GNFT ) stock rose over the last week. Despite the strong profit...

분석 기사 • Sep 26

Genfit S.A. (EPA:GNFT) Held Back By Insufficient Growth Even After Shares Climb 26%

Genfit S.A. ( EPA:GNFT ) shares have continued their recent momentum with a 26% gain in the last month alone. Looking...

분석 기사 • Sep 24

Growth Investors: Industry Analysts Just Upgraded Their Genfit S.A. (EPA:GNFT) Revenue Forecasts By 28%

Celebrations may be in order for Genfit S.A. ( EPA:GNFT ) shareholders, with the analysts delivering a significant...

분석 기사 • Sep 22

Genfit (EPA:GNFT) Seems To Use Debt Quite Sensibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

분석 기사 • May 23

Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

The Genfit S.A. ( EPA:GNFT ) share price has done very well over the last month, posting an excellent gain of 28...

분석 기사 • Jan 03

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Genfit S.A. ( EPA:GNFT ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...

분석 기사 • Jun 29

Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

The latest analyst coverage could presage a bad day for Genfit S.A. ( EPA:GNFT ), with the analysts making...

분석 기사 • Mar 14

Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. Imagine if you held...

이익 및 매출 성장 예측

ENXTPA:GNFT - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	101	-11	9	-2	5
12/31/2027	112	2	0	1	6
12/31/2026	88	-6	-12	-8	2
12/31/2025	65	-86	-30	-26	N/A
9/30/2025	55	-62	-18	-15	N/A
6/30/2025	45	-39	-7	-3	N/A
3/31/2025	58	-19	4	6	N/A
12/31/2024	71	2	15	16	N/A
9/30/2024	76	12	-14	-13	N/A
6/30/2024	80	22	-43	-42	N/A
3/31/2024	57	-3	-50	-48	N/A
12/31/2023	34	-29	-58	-55	N/A
9/30/2023	32	-32	-55	-53	N/A
6/30/2023	29	-34	-52	-50	N/A
3/31/2023	28	-29	-62	-61	N/A
12/31/2022	26	-24	-73	-73	N/A
9/30/2022	60	12	4	4	N/A
6/30/2022	94	48	80	80	N/A
3/31/2022	90	58	90	90	N/A
12/31/2021	85	67	99	100	N/A
9/30/2021	46	14	10	11	N/A
6/30/2021	6	-39	-79	-79	N/A
3/31/2021	7	-70	-88	-88	N/A
12/31/2020	9	-101	-97	-96	N/A
9/30/2020	24	-84	-73	-71	N/A
6/30/2020	39	-67	-49	-46	N/A
3/31/2020	39	-66	-49	-47	N/A
12/31/2019	39	-65	-50	-48	N/A
9/30/2019	23	-80	N/A	-60	N/A
6/30/2019	8	-94	N/A	-71	N/A
3/31/2019	8	-87	N/A	-64	N/A
12/31/2018	7	-80	N/A	-56	N/A
9/30/2018	7	-75	N/A	N/A	N/A
6/30/2018	7	-70	N/A	-56	N/A
3/31/2018	7	-63	N/A	-53	N/A
12/31/2017	7	-56	N/A	-50	N/A
9/30/2017	7	-50	N/A	N/A	N/A
6/30/2017	8	-44	N/A	-40	N/A
3/31/2017	7	-39	N/A	-34	N/A
12/31/2016	7	-34	N/A	-27	N/A
9/30/2016	6	-27	N/A	-23	N/A
6/30/2016	5	-21	N/A	-18	N/A
3/31/2016	5	-19	N/A	-16	N/A
12/31/2015	4	-17	N/A	-15	N/A
9/30/2015	5	-17	N/A	-17	N/A
6/30/2015	5	-17	N/A	-19	N/A

애널리스트 향후 성장 전망

수입 대 저축률: GNFT 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(2.5%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: GNFT (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: GNFT 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: GNFT 의 수익(연간 8%)이 French 시장(연간 5.6%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: GNFT 의 수익(연간 8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: GNFT의 자본 수익률은 3년 후 51%로 매우 높을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/25 21:10
종가	2026/05/25 00:00
수익	2025/12/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Genfit S.A.는 14명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Geoffrey Meacham	BofA Global Research
Arnaud Cadart	CIC Market Solutions (ESN)
Alethia Young	Deutsche Bank

Genfit 향후 성장

Future 기준 점검 5/6

핵심 정보

최근 향후 성장 업데이트

Consensus revenue estimates fall by 24%

Price target decreased by 7.4% to €8.78

Consensus revenue estimates decrease by 13%

Consensus revenue estimates fall by 79%

Consensus revenue estimates fall by 80%

Consensus EPS estimates fall by 54%

Recent updates

Genfit S.A., Annual General Meeting, Jun 15, 2026

Genfit S.A. to Report Fiscal Year 2025 Results on Apr 02, 2026

GENFIT Announces Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N

Genfit S.A. Announces Appointment of Pejvack Motlagh as Chief Medical Officer

Genfit S.A.(NasdaqGS:GNFT) dropped from NASDAQ Composite Index

GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting®?2025

New minor risk - Share price stability

Consensus revenue estimates fall by 24%

First half 2025 earnings: EPS and revenues miss analyst expectations

Price target decreased by 7.4% to €8.78

These Analysts Just Made An Downgrade To Their Genfit S.A. (EPA:GNFT) EPS Forecasts

Genfit S.A. Announces Management Changes

GENFIT Announces Discontinuation of its VS-01 Program in ACLF

Some Analysts Just Cut Their Genfit S.A. (EPA:GNFT) Estimates

Consensus revenue estimates decrease by 13%

Consensus revenue estimates fall by 79%

Shareholders Will Probably Not Have Any Issues With Genfit S.A.'s (EPA:GNFT) CEO Compensation

Consensus revenue estimates fall by 80%

Improved Revenues Required Before Genfit S.A. (EPA:GNFT) Stock's 29% Jump Looks Justified

Solid Earnings Reflect Genfit's (EPA:GNFT) Strength As A Business

Genfit S.A. Announces Efficacy Results of Ipsen’s Phase 2 ELMWOOD Trial

These 4 Measures Indicate That Genfit (EPA:GNFT) Is Using Debt Reasonably Well

Full year 2024 earnings released: EPS: €0.03 (vs €0.58 loss in FY 2023)

Consensus EPS estimates fall by 54%

New major risk - Revenue and earnings growth

GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025

Genfit S.A., Annual General Meeting, Jun 17, 2025

Genfit S.A. to Report Fiscal Year 2024 Results on Apr 24, 2025

Genfit S.A. (EPA:GNFT) Not Doing Enough For Some Investors As Its Shares Slump 25%

Investor sentiment deteriorates as stock falls 20%

Consensus EPS estimates increase by 21%, revenue downgraded

We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit

Investor sentiment improves as stock rises 26%

Genfit S.A. (EPA:GNFT) Held Back By Insufficient Growth Even After Shares Climb 26%

First half 2024 earnings: EPS and revenues exceed analyst expectations

Growth Investors: Industry Analysts Just Upgraded Their Genfit S.A. (EPA:GNFT) Revenue Forecasts By 28%

Genfit (EPA:GNFT) Seems To Use Debt Quite Sensibly

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

New minor risk - Share price stability

Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

New minor risk - Share price stability

Genfit S.A., Annual General Meeting, May 22, 2024

Genfit S.A.'s (EPA:GNFT) 26% Price Boost Is Out Of Tune With Revenues

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 38%, EPS downgraded

GENFIT Announces Publication in Nature Medicine Confirming the Performance of Its Nash Diagnostic Technology

First half 2023 earnings released: €0.42 loss per share (vs €0.21 loss in 1H 2022)

Health Check: How Prudently Does Genfit (EPA:GNFT) Use Debt?

New minor risk - Profitability

Consensus EPS estimates increase by 291%

Genfit S.A. Announces the Publication of New Data on the Clinical Performance of NIS2+(TM) in Older Patients in Hepatology Communications

New minor risk - Profitability

Price target increased by 9.4% to €9.72

Revenue Downgrade: Here's What Analysts Forecast For Genfit S.A. (EPA:GNFT)

Consensus revenue estimates decrease by 21%

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Price target increased by 9.4% to €9.70

New minor risk - Share price stability

Genfit S.A. (EPA:GNFT) Investors Are Less Pessimistic Than Expected

Price target decreased by 11% to €8.84

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week as part of its ACLF Program

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.1% to €9.20

Genfit S.A. to Report First Half, 2023 Results on Sep 20, 2023

We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease